{"nctId":"NCT01741701","briefTitle":"A Pilot Study of Oxaloacetate in Subjects With Treated PD","startDateStruct":{"date":"2012-12"},"conditions":["Parkinson's Disease"],"count":33,"armGroups":[{"label":"Oxaloacetate (OAA)","type":"EXPERIMENTAL","interventionNames":["Drug: Oxaloacetate (OAA)"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"Oxaloacetate (OAA)","otherNames":["benaGeneâ„¢"]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Able to give informed consent and follow instructions per the protocol\n* Diagnosis of idiopathic PD within 7 years of diagnosis\n* Taking stable doses of levodopa and would not predictably need adjustment in PD medications for 4 months\n* Unified Parkinson's Disease Rating Scale (UPDRS) II + III at least 30 points at baseline\n\nExclusion Criteria:\n\n* Previously taken Oxaloacetate\n* Participation in other drug studies or use of other investigational products within 30 days prior to baseline\n* In the Investigator's opinion, any unstable or clinically significant condition that would impair the subjects' ability to comply with study follow-up\n* Other known or suspected cause of parkinsonism","healthyVolunteers":false,"sex":"ALL","minimumAge":"30 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Unified Parkinson's Disease Rating Scale (UPDRS) Total Score","description":"The UPDRS has 3 subscales including Mentation (4 questions based on patient report with answers on a scale of 0-4, with a total of 16 points), Activities of Daily Living (13 questions based on patient report with answers on a scale of 0-4, with a total of 52 points) and Motor (27 questions based on clinician assessment on a scale of 0-4, with a total of 108 points). The total scores represents the sum of each of these sections for a total of 176 points with a higher score representing greater dysfunction.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"41.1","spread":"6.7"},{"groupId":"OG001","value":"42.9","spread":"10.8"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"34.9","spread":"10.4"},{"groupId":"OG001","value":"34.4","spread":"12.4"}]}]}]},{"type":"SECONDARY","title":"Unified Parkinson's Disease Rating Scale (UPDRS) ADL + Motor Score","description":"The UPDRS has 3 subscales including Mentation (4 questions based on patient report with answers on a scale of 0-4, with a total of 16 points), Activities of Daily Living (13 questions based on patient report with answers on a scale of 0-4, with a total of 52 points) and Motor (27 questions based on clinician assessment on a scale of 0-4, with a total of 108 points). This measure examined the ADL + Motor subscales which have a total of 160 points with a higher score representing greater dysfunction.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"39.4","spread":"6.9"},{"groupId":"OG001","value":"42.2","spread":"10.7"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"33.4","spread":"10.2"},{"groupId":"OG001","value":"33.9","spread":"11.7"}]}]}]},{"type":"SECONDARY","title":"Parkinson's Disease Questionnaire - 39 (PDQ-39)","description":"The PDQ-39 is a measure of quality of life in Parkinson's disease patients. It has 39 questions each with a response from 0-4 for a total of 156 points. The total score is calculated as a percentage so the scores of the 39 items are added and divided by 156 and multiplied by 100. The higher the score the worse quality of life.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13.0","spread":"8.9"},{"groupId":"OG001","value":"10.1","spread":"7.8"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14.4","spread":"11.2"},{"groupId":"OG001","value":"11.3","spread":"7.4"}]}]}]},{"type":"SECONDARY","title":"Montreal Cognitive Assessment (MoCA)","description":"The MoCA is an assessment of cognitive function. The total possible score ranges from 0 to 30 points with a lower score representing greater cognitive impairment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"27.4","spread":"2.0"},{"groupId":"OG001","value":"27.2","spread":"2.4"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"28.1","spread":"1.6"},{"groupId":"OG001","value":"27.6","spread":"2.4"}]}]}]},{"type":"SECONDARY","title":"Geriatric Depression Scale (GDS)","description":"The GDS is a measure of depression. The scale has 30 yes/no questions. Each question has a maximum score of 1 and a total possible score ranging from 0 to 30. The higher the score the greater the depression.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.3","spread":"4.4"},{"groupId":"OG001","value":"3.3","spread":"3.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.8","spread":"5.4"},{"groupId":"OG001","value":"3.8","spread":"3.7"}]}]}]},{"type":"SECONDARY","title":"NonMotor Symptom Questionnaire (NMSQuest)","description":"The NMSQuest is a 30 item questionnaire with 30 yes/no questions. There is a total of 30 points with each \"yes\" score representing 1 point and therefore the higher the score the greater number of nonmotor symptoms present. The score can range from 0 to 30.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.1","spread":"4.4"},{"groupId":"OG001","value":"6.2","spread":"4.4"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.9","spread":"6.3"},{"groupId":"OG001","value":"6.9","spread":"4.6"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":18},"commonTop":["Worsening of Parkinson's disease","insomnia/stimulant","GI upset","Fatigue","Cognitive worsening"]}}}